Generic Name:Tetracycline (Tetracycline Hydrochloride) Solution
This medicine is a Prescription Medicine Medicine. You must have an
Condition of Useof Tetracycline hydrochloride. This condition is only a temporary and may occur long term.
for the treatment of tetracycline-associated infections. This medicine is only for use in the skin and eyes.
Tetracycline may have potential interactions with other medications. Tell your doctor about any prescription or over-the-counter (OTC) medications, herbal products you are using, and stop using them immediately if you notice any unwanted effects.
Tetracycline is not recommended for use in pregnant or breastfeeding women unless considered medically necessary. Women who are pregnant or may become pregnant should not handle crushed or broken Tetracycline tablets. Avoid contact of the tablets with eyes. Do not use expired Tetracycline. It should not be swallowed, squeezed, or chewed. Children under 12 years may be at a higher risk of having an eye infection than adults. Tetracycline is not recommended for use in elderly patients (over 65 years) or for patients (recently) with chronic kidney disease. It is not known whether Tetracycline can be used in patients with diabetes mellitus. It is not known whether Tetracycline can be used in patients with epilepsy. It is not known whether Tetracycline can be used in patients with liver disease.
If you are using Tetracycline for the treatment of tetracycline-associated infections, it is important that you do not use this medication if you have ever had a serious allergic reaction to Tetracycline or any other tetracycline antibiotic. Tetracycline antibiotics (such as Tetracycline) can cause allergic reactions, including but not limited to: allergic skin reactions; difficulty in breathing; stomach pain; dizziness; skin rash; and/or watery or bloody stools. Contact your doctor right away if you experience any of the symptoms listed below.
Background:Sulfamethoxazole-related drug resistance has been the leading cause of drug-resistant bacteria worldwide and is a major public health issue affecting approximately 10–25% of all healthcare expenditures worldwide. The objective of this study was to evaluate the efficacy of oral sulfamethoxazole and tetracycline in the treatment of drug-resistantBacillus anthracis(B. anthracis).
Methods:Bacterial isolates were obtained from clinical trials of seven commonly prescribed drugs for B. anthracis and were screened for resistance to sulfamethoxazole-trimethoprim. Resistance was evaluated using MIC assay and resistance was graded as follows:B. anthracisresistant,susceptible to sulfamethoxazole-trimethoprim, andsusceptible to tetracycline-trimethoprim.
Results:Forty-one clinical trials were conducted for the treatment of B. anthracis. anthracis was more resistant to tetracycline than to sulfamethoxazole. The resistance to tetracycline was not higher in patients with a clinical infection who received oral sulfamethoxazole-trimethoprim, or tetracycline-trimethoprim, than in patients with a clinical infection who received oral tetracycline-trimethoprim.
Conclusion:The efficacy of oral sulfamethoxazole-trimethoprim in the treatment of B. anthracis is not as good as that of tetracycline-trimethoprim.
Bacterial resistance to a broad-spectrum antibiotic, including sulfonamides, has become a significant public health problem affecting approximately 10–25% of all healthcare expenditures worldwide []. This has led to the development of new therapeutic options for bacterial infections, such as the use of broad-spectrum antibiotics [, ]. The development of resistance to many drugs, including tetracyclines, has also contributed to the development of resistance to the most common classes of antibiotics []. The current situation is very different, with an increasing prevalence of drug-resistant pathogens and a rise in the number of new drug-resistant bacterial species [].
A broad-spectrum antibiotic, sulfonamide antibiotics, is widely used to treat many bacterial infections including bacterial conjunctivitis, cellulitis, bronchitis, and sexually transmitted infections (STIs). However, the development of resistance to these antibiotics is a major public health concern worldwide, and a substantial fraction of the global population (i.e., about 10–25%) has been identified as the target of this issue. The global prevalence of sulfonamide resistance is increasing, with the rate of antimicrobial resistance (AMR) increasing with age []. In addition, the development of drug resistance in bacteria has resulted in an increased global burden of bacterial infections, resulting in a greater number of cases of disease, morbidity, and mortality [].
A broad-spectrum antibiotic is a broad-spectrum antibiotic that has been used in several clinical infections for many years. However, resistance to tetracyclines, sulfonamides, and other classes of antibiotics has also been reported [, ]. A number of factors can contribute to the development of resistance to a broad-spectrum antibiotic, including the use of broad-spectrum antibiotics, increasing resistance, and the development of drug-resistant bacteria. The prevalence of drug-resistant bacteria is increasing, with the number of new drug-resistant bacterial species increasing over the past decades [, ].
Bacterial resistance to a broad-spectrum antibiotic is a significant public health concern worldwide, and it has been estimated that the global prevalence of drug-resistant bacteria is about 5–10% [–]. The most common antibiotic-resistant bacteria are Gram-positive bacteria (i.e.,Streptococcus pyogenes), and most are found in the gastrointestinal tract of humans and animals, especially among patients with gastrointestinal infections []. The prevalence of antibiotic-resistant bacteria is higher in people with a history of bacterial gastrointestinal disease, such as chronic bacterial diarrhea, acute bacterial peritonitis, and infectious diarrhea, which is common in older adults [, ]. Bacterial resistance to tetracyclines has been demonstrated in clinical trials for patients with a history of gastrointestinal disease [, ].
Save16%
Original price$ 319.00
Current price$ 269.00
SKU23155-0767-01
Medical Professional License Required to Unlock Account(Note: We don’t Fill Personal Prescriptions)How to Order:
✔Send an email request to: [email protected]
You will receive instructions on how to create an account along with Rx Ordering Details.
Tetracycline HCl Capsules USP 500 mg is an antibiotic medication used to treat a variety of bacterial infections, including respiratory tract infections, skin infections, and urinary tract infections. It belongs to a class of antibiotics called tetracyclines, which work by preventing the growth and spread of bacteria. This medication should only be used to treat bacterial infections and will not work for viral infections such as the common cold or flu. Tetracycline HCl Capsules USP 500 mg is a prescription medication used to treat bacterial infections, including those involving the skin, respiratory tract, urinary tract, and digestive system. It can also be used to treat certain sexually transmitted infections and other conditions as determined by a doctor. The capsules are usually taken orally and the dosage and length of treatment will depend on the specific infection being treated. It is important to finish the full course of treatment prescribed by the doctor, even if the symptoms improve. It is important to take Tetracycline HCl Capsules USP 500 mg on an empty stomach (at least one hour before or two hours after meals) with a full glass of water. This medication should not be taken with dairy products, antacids, or iron supplements, as they can decrease the effectiveness of the medication. If the medication is being used to treat an infection, symptoms should start to improve within a few days. However, it is important to continue taking the medication for the prescribed length of time to ensure that the infection is fully treated and to prevent bacteria from becoming resistant to the antibiotic. If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule should be resumed. Tetracycline HCl Capsules USP 50 mg may interact with other medications and supplements, so it is important to inform the doctor of any other medications being taken. It is also important to let the doctor know if there are any allergies to tetracycline or other antibiotics. Possible side effects of Tetracycline HCl Capsules USP 500 mg include nausea, vomiting, stomach upset, diarrhea, loss of appetite, and headache. If these side effects are severe or persistent, it is important to inform the doctor. If any serious side effects occur, such as difficulty breathing, yellowing of the skin or eyes, or symptoms of a severe allergic reaction, seek medical attention immediately. It is important to complete the full prescribed course of treatment for Tetracycline HCl Capsules USP 500 mg, even if symptoms improve, in order to fully eradicate the infection and prevent bacteria from becoming resistant to the medication.
Read moreProduct Name: Tetracycline HCl Capsules USP 500 mg USP 100 Count (RX)
Active Ingredients: Tetracycline HCl
Dosage: 5 – 28 capsules daily for 10 days
Warnings: This medication may not be used for children under 12 years of age. It is recommended to use only as prescribed by a doctor. If you are using any supplements or medications, it is important to inform your doctor or pharmacist before starting treatment. It is important to complete the prescribed course of Tetracycline HCl Capsules USP 500 mg, even if symptoms improve, in order to fully eradicate an infection and prevent bacteria from becoming resistant to the medication. This medication should be completed for Tetracycline HCl Capsules USP 500 mg to be effective. If a dose is missed, it should be taken as soon as it should be.
The objective of this study was to create an inducible promoter system for the production of tetracycline-responsive promoters insystems with minimal cell-to-cell variation.
Figure 1Preparation of cotransfected pMTT-TTA-GFP vectors.
First, we constructed a transgenic vector carryingTTA-GFPgene. The expression of thegene was confirmed by PCR, and the promoter and promoter-containing sequences were inserted into pEGFP-TTA-GFP plasmid vector. Thegene-expressing vector was generated by the first round of transformation ofgene-expressing cells with the pMTT-TTA-GFPThen, thegene was cloned into the plasmid vector by the first round of transfection, and thegene-expressing cells were co-transfected with the pEGFP-TTA-GFPgene-expressing plasmid.gene-expressing cells were selected on the plates for at least 3 days.
The transgenic plasmids were used to expressThe promoter-containing sequence ofgene was cloned into the pEGFP-TTA-GFPGFP plasmid. The pMTT-TTA-GFPGFP transgenic vector was generated by the first round of transfection.GFP transgenic plasmid was co-transfected with the pMTT-TTA-GFPGFP transgenic plasmid. After the pMTT-TTA-GFPGFP transgenic plasmid was transfected into thegene-expressing cells, theGFP transgenic plasmid was selected on the plates for at least 3 days.GFP transgenic plasmid was co-transfected with pMTT-TTA-GFPgene-expressing cells.
gene-expressing cells were then selected on the plates for at least 3 days.gene-expressing cells were then cultured in a humidified 5% CO2 atmosphere at 37°C with 5% of relative humidity. The growth medium was replaced every 3 days.
Next, we constructed aGFP transgenic plasmid by the first round of transfection.
Stade de France Pharmacy